INTRODUCTION 1
DprE1 is an essential flavoprotein of Mycobacterium tuberculosis involved in 2 decaprenylphosphoryl-beta-D-arabinose (DPA) synthesis. DPA is the sole precursor of arabinose 3 for production of both arabinogalactan and lipoarabinomannan (1) , important components of the 4 mycobacterial cell wall. DprE1, together with its counterpart DprE2, catalyse the epimerization 5 of decaprenylphosphoryl-ß-D-ribose (DPR) to DPA in a two-step mechanism. In the last decade, 6 many inhibitors were discovered to target DprE1, which is considered nowadays as the Achilles ' 7 heel of M. tuberculosis due to its essentiality and especially to its localization in the periplasm 8
(2). DprE1 inhibitors can be classified into two families according to their mode of action: some 9 of them inhibit DprE1 irreversibly by forming a covalent adduct with cysteine 387 (C387) of 10 DprE1, whereas others act as competitive non-covalent inhibitors (3) . 11
The first covalent DprE1 inhibitors discovered were benzothiazinones (BTZ), exemplified 12 by the lead compound, BTZ043, which is exceptionally potent with in vitro and ex vivo minimal 13 inhibitory concentration (MIC) values in the nanomolar range (4) . A lead optimization campaign 14 gave rise to PBTZ169, now known as Macozinone (MCZ). It is currently the most potent BTZ 15 compound against M. tuberculosis with an MIC of 0.3 nM (5), has completed preclinical 16 development successfully and is now undergoing Phase I and phase II clinical trials 17 (https://www.newtbdrugs.org/pipeline/clinical). A common characteristic of the covalent DprE1 18 inhibitors is the presence of a nitro group on the molecule, which is essential for the mechanism 19 of inhibition. Indeed, this nitro group is converted by DprE1 containing FADH 2 into an extremely 20 reactive nitroso group which specifically targets the cysteine residue at position 387 (C387) in the 21 active site of DprE1, to form a covalent adduct and thereby irreversibly inhibits the enzyme (4) (5) (6) (7) 22 Synthesis of sPBTZ. The synthesis of 17 sulfanyl-piperazino BTZ (sPBTZ) derivatives 1 was performed in a two-step procedure from 2-(methylthio)-8-nitro-6-(trifluoromethyl)-4H-1,3-2 benzothiazin-4-one, as described previously (Makarov et al., 2014) . Its reaction with a 5-molar 3 excess of free piperazine generated the corresponding piperazine derivative with a high yield. 4
This scaffold was used in the reactions with different alkyl-, aryl-or heteryl-sulfochlorides to 5 form sulfanyl-piperazino BTZs. The compounds synthesized have different types of sulfonyl 6 substitutions thus allowing the structure-activity relationship to be studied. It is clear that 7 compounds with alkyl substitutions have much better antitubercular activity and aryl derivatives 8 have much lower activity, consistent with our previous data for piperazine-containing BTZ 9 (PBTZ) derivatives (Makarov et al., 2014) . 10
Solubility. The octanol-water partition coefficient, logP, which is regarded as a suitable 11 indicator of molecular hydrophobicity and bioavailability, was calculated for all derivatives to 12 measure the effects of introducing a sulfonyl group on the PBTZ backbone. Interestingly, the 13 addition of the sulfonyl group between the benzothiazinone and piperazine moieties has the 14 tendency to decrease the clogP coefficient and therefore hydrophobicity ( Table 1 ). The 15 sulfonylated derivative of MCZ, sPBTZ169 (11326127) that carries a sulfonyl group between the 16 piperazine and cyclohexyl moieties, has a clogP of 3.28 whereas MCZ has a clogP of 4.31. This 17 implies that the introduction of a sulfonyl group decreases hydrophobicity, and may thus increase 18 solubility in physiological conditions and subsequently could have an important impact on 19 bioavailability. 20 Antitubercular activity. The activity of all sPBTZ derivatives was tested in vitro against 21 M. tuberculosis H37Rv and MIC 99 values were determined (Table 1) . Most sPBTZ were active in 22 vitro in the sub-micromolar range, proving that that addition of the sulfonyl group does not 23 abolish activity. However, none has a better activity than MCZ. 11626093, which has a butyl 1 group, has the highest activity of MIC 1 ng/µL corresponding to 5 times the MIC 99 of MCZ. The 2 introduction of a sulfone between the piperazine and the cyclohexyl negatively affected the 3 activity of the compound, reducing activity by 30 fold, as observed with sPBTZ169 (11326127), 4 which has an MIC 99 of 6 nM. It was previously shown that substituting the methylcyclohexyl in 5 MCZ with small radicals such as methyl or ethyl decreases the activity of compounds, with MIC 6 of 250 ng/mL and 60 ng/mL, respectively (5) . Interestingly, when methylcyclohexyl is 7 substituted by sulfonylmethyl (11626095) or sulfonylethyl (11626092), the activity decreases less 8 and the compounds are 10-times more active that the non-sulfonated derivatives (MIC of 20 9 ng/mL and 3 ng/mL, respectively). Substitution with a butyl leads to the same activity 10 independent of the sulfonyl group. This observation indicates that the presence of the sulfonyl 11 group positively affects activity when the radical is small (methyl or ethyl) whereas it negatively 12 influences activity when the substituent is long and hydrophobic. 13
Similarly to the other BTZ derivatives, the activities of the sulfonyl derivatives are 14 inversely proportional to the logP (4), suggesting that activity could be related to solubility in 15 lipids ( Figure S1 ). Seven molecules were selected based on their activity/logP profile for further 16 characterisation ( Figure S1 ). 17
Target engagement and structural studies. To ensure that sPBTZs specifically target 18 DprE1, selected sulfonyl derivatives were tested against M. tuberculosis NTB1, a DprE1 mutant 19 that carries a cysteine 387 serine (C387S) substitution and is thus resistant to BTZ. As expected, 20 none of the sBTZs are active against NTB1, indicating that DprE1 is their only target (Table 2) . 21 Furthermore, it is evident that the sulfonyl group is unable to mimick the carboxylate moiety of 22 2-carboxyquinoxalines in stabilising the compound in the pocket as a non-covalent inhibitor. 23
To investigate whether the introduction of the sulfonyl group could influence the position 1 of the inhibitor and allow more contact within the binding pocket, a crystal structure of DprE1 in 2 complex with sPBTZ169 was solved and compared to the crystal structure of DprE1 with MCZ. 3 sPBTZ169 is located in the same pocket as MCZ and other BTZ derivatives. It sits in an 4 hydrophobic pocket via the trifluoromethyl group and is covalently bound to C387 (Figure 1 ). 5
The compound is maintained by Van der Walls interaction on each side by V365, Y314, W230 6 and FAD, and a hydrogen bond between K418 and the oxygen atom of the nitro group of 7 sPBTZ169. Unfortunately, the orientation of sPBTZ does not favor the formation of a new 8 anchor to the protein for instance interaction between the sulfonyl function and Y60. Futhermore 9 as MCZ, the electron density map does not account fully for the sulfonyl-cyclohexyl moiety of 10 sPBTZ169 likely due to its higher flexibility demonstrating that sulfonyl is not stabilized in the 11 pocket ((5)). 12
To determine whether the sulfonyl group could affect the activity at the protein level and 13 even help to stabilize the inhibitor in the active site of a BTZ-resistant C387S DprE1 variant, the 14 inhibition of DprE1 activity was measured in vitro. IC 50 values were determined for the wild type 15 and the BTZ-resistant C387S mutant enzyme for MCZ and sPBTZ169 (Table S2 ). sPBTZ169 16 has an IC 50 of 1.1 and 12 µM against wild type and BTZ-resistant DprE1, respectively, whereas 17 the corresponding IC 50 values for MCZ are 0.3 and 3.6 µM. That introducing the sulfonyl group 18 on the MCZ scaffold leads to 4-fold less activity suggests that even if the environment of the 19 protein is favorable for an H-bond acceptor, the presence of a hydrophobic group, such as a 20 cyclohexyl in MCZ, is still preferable for activity of the drug. On the other hand, the higher IC 50 21 against C387S compared to the WT enzyme validates the structural studies in that the sulfonyl 22 group does not help to stabilize the molecule in the pocket of the BTZ-resistant mutant C387S. 23 ADME/T. To assess potential cytotoxic effects of the sulfonyl group on the sPBTZ 1 derivatives, viability of HepG2 cells was monitored after exposure to different concentrations of 2 the compounds. The concentration for half-maximal cytotoxicity (TD 50 ) was determined for each 3 compound. Four of the seven compounds were not cytotoxic (11326059, 11326127, 11626093, 4 1162694) while three of them showed mild cytotoxicity at concentrations of around 10 µg/mL 5 (1162691, 1162692, 1162695) . Taken together, the selective index representing the ratio of the 6 antitubercular activity of compounds (MIC 99 on H37Rv) to cytotoxicity (TD 50 on HepG2 cells) is 7 more than acceptable for the chosen seven compounds. 8
Since solubility issues are often encountered in drug development, which would 9 consequently impact bioavailability and activity in vivo, the solubility of these derivatives was 10 calculated by the shake flask method in equilibrium in water. Experimental solubility constants 11 measured were then compared to theoretical solubility constants calculated using the 12 SwissADME webserver (26). sPBTZ are predicted to have increased solubility compared to 13 MCZ in water (Table 3 ) and experimental solubility constants measured in water for all sPBTZ 14 derivatives are consistent with theoretical constants calculated by SwissADME using different 15 algorithms ( Table 3 ). As expected, 11626095, 11626092 and 11626091, harboring methyl, ethyl 16 and cyclopropyl groups, respectively, are the most soluble sPBTZ derivatives. In contrast, 17 11326059, 11326127, 11626093, and 11626094 that carry bigger hydrophobic groups are at least 18 100-times less soluble in water. Interestingly, there is a good correlation between water solubility 19 and clogP. However, a discrepancy between the predicted and experimental solubility for MCZ 20 was observed. In fact, MCZ is 400 times more soluble in water than calculated with different 21
algorithms. 22
Another possible issue in the development of MCZ might be metabolic instability (5) . In 1 order to test if the sulfonyl group could improve metabolic stability effected by mouse or human 2 liver enzymes, microsomal stability experiments were conducted. Compounds 11626095, 3 11626091 and 11626092 harbouring the smallest radical chains methyl, ethyl and cyclopropyl, 4 respectively, have the lowest clearances in both mouse and human microsomes, indicative of 5 their stability. 11626093 carrying a butyl radical is metabolically stable in human but highly 6 unstable in mouse microsomes, suggesting that it could be a good substrate for mouse but not 7 human microsomal enzymes. Compounds 11326059 and 11326127 have medium clearances, 8 similar to MCZ and BTZ043. Of note, 11626094 is highly unstable in the presence of human 9 microsomes. These results reveal a strong correlation between the length of the substituent after 10 the piperazine moiety and instability in microsomes. 11
Activity in the murine model of chronic TB. Finally, the in vivo efficacy of 1162691 12 was assessed in the murine model of chronic TB following low-dose aerosol infection of 13 BALB/cByJ mice with M. tuberculosis and treatment at 50 mg/kg ( Figure 2 ). Compound 14 1162691 was selected as it is the most promising taking into account its activity ("only" 15 times 15 less active than MCZ), cytotoxicity, solubility, and metabolic stability properties. 16
Compared to the untreated control group, the bacterial burden in the lungs and spleens of 17 1162691-treated mice was 0.46 (*) and 1.03 (***) log 10 CFU lower, respectively (Fig 2) , whereas 18 the values for those organs from MCZ-treated mice were 1.03 (***) and 1.47 (***) log 10 CFU. 19
These results indicate that 1162691 is highly active in vivo in the murine model of chronic TB, 20
although it is less able to reduce the bacterial load in the lungs than treatment with MCZ. 21
Interestingly, 1162691 seems to be more efficacious in the spleen than in lungs. 22
DISCUSSION 1
Lead compounds for new anti-TB drugs should possess not only potent sterilizing activity but 2 also good pharmacokinetic profiles to facilitate their co-administration with other anti-TB and 3 anti-HIV (human immunodeficiency virus) agents. New drugs should also be appropriate for 4 once daily oral dosing and be relatively inexpensive to produce to ensure that all high-burden 5 countries have access. Structure-based rational drug design supports drug development and has 6 the potential to increase the activity and pharmacokinetic properties of lead compounds. 7
The new sPBTZ series was designed as part of the MCZ back-up program. MCZ is a 8 BCS (biopharmaceutical classification system) class 2 drug with a low dissolution rate but 9 excellent absorption (5) . Structural studies indicate that the environment of the binding pocket in 10 the protein can accommodate a polar group at the cyclohexyl position of MCZ (3). A sulfonyl 11 group was deemed to be a good candidate because it is well characterized and present in many 12 soluble and metabolically stable FDA-approved drugs including those for treating mycobacterial 13 infections. For instance, sulfamethoxazole is a sulfonamide drug used in co-trimoxazole 14 prophylaxis for HIV-infected patients, demonstrating that it is compatible with anti-retroviral 15 treatment (27). 16
It was previously shown that there is a strong correlation between logP and BTZ activity 17 (4) . We found that introduction of a sulfonyl group into the MCZ scaffold to form the sPBTZ 18 series decreases both logP and activity in vitro (Table 1) . However, sPBTZ still retain potency 19 and the presence of the sulfonyl group improved aqueous solubility for those derivatives, which 20 harbour small side chains, such as methyl, ethyl or cyclopropyl, as compared to MCZ (5) . 21
Interestingly, aqueous solubility and metabolic stability measured in microsomes indicate a better 22 behaviour for sPBTZ with small groups rather than those with long hydrophobic chains or MCZ. 23
Despite being less active than MCZ our sulfonylated PBTZ with long hydrophobic chains, 1 methyl (11626095), ethyl (11626092) or cyclopropyl (11626091) derivatives are considered as 2 good candidates in terms of their solubility and metabolic stability profiles. The efficacy of the 3 most active derivative of the three, 11626091, was assessed in vivo in the murine model of 4 chronic TB, where relatively good activity was measured in the lungs and particularly in the 5 spleens ( Figure 2 ). It is also important to note that dissolution of 11626091 was considerably 6 easier than MCZ in methylcellulose, the solvent used for the in vivo studies (technical 7 observation, data not shown). 8
One of the objectives of inserting a sulfonyl group into the PBTZ backbone was to 9 increase mitigate potential BTZ-resistance by increasing the number of hydrogen bonds with 10 DprE1. Indeed, a sulfonyl could act as an H-bond acceptor in order to anchor the protein to the 11 H-bond donors, for example the hydroxyl group of Tyrosine 60 localized in the binding pocket. 12
This group was identified as a key player in the stabilization of 2-carboxyquinoxalines, molecules 13 that remain active against BTZ-resistant DprE1. Unfortunately, as was observed in the crystal 14 structure and enzymatic inhibition assays, the sulfonyl group of sPBTZ is not implicated in the 15 binding and stabilization of the drug in the pocket as originally hypothesized. This explains the 16 resistance of the BTZ-resistant M. tuberculosis mutant NTB1 to sPBTZ. 17
To conclude, our study identifies 11626091 as an active, metabolically stable and 18 moderately soluble molecule that is less active than MCZ in vitro and in vivo. However, given its 19 better solubility, compound 11626091 represents an attractive back-up to MCZ, that should now 20 be tested in combination with other TB drug candidates such as bedaquiline in order to assess its 21 potential to contribute to a new regimen. 22
MATERIALS AND METHODS 1
Synthesis. The synthetic route used to produce sPBTZ and related procedures are 2 described in the supporting materials. Cytotoxicity studies. The cytotoxicity of the compounds was measured as described 20 previously against the human hepatic cell line, HepG2, (20). Briefly, cells were incubated (4,000 21 cells/well) with serial dilutions of compounds (2-fold dilutions; 100 to 0.1 µg/ml) in a 96-well 22 microplate. Following incubation for 3 days at 37°C cell viability was determined by adding 23 resazurin for 4 h at 37°C and measuring the fluorescence of the resorufin metabolite (excitation 1 wavelength, 560 nm; emission wavelength, 590 nm) using a Tecan Infinite M200 microplate 2 reader. Data were corrected for background (no-cell control) and expressed as a percentage of the 3 value for untreated cells (cells only). 4
Data were fitted to obtain IC 50 values, using "Log(inhibitor) vs. response -Variable 5 slope" function implemented in GraphPad Prism software version 7.0 (GraphPad Software, Inc., 6
La Jolla, CA, USA). Selective index refers to the ratio of the dose of drug that causes toxicity 7 effects (TD50) to the dose that leads to the desired pharmacological effect (MIC 99 ). 8
Water Solubility. Water solubility measurements were performed using the shake flask 9 method ((28)). Approximately 1 mL was added to 1 mg of compound in an Eppendorf tube and 10 incubated for 3 days at 25°C with shaking at 800 rpm. Suspensions were centrifuged at 16,100 x 11 g for 10 min and the supernatant filtered using 0.22 µ filters. Filtrates were injected onto a high-12
performance liquid chromatography (HPLC) column (Dionex) and the amount of compound 13 quantified using a calibration curve. 14
Inhibition assays, crystallography and structural studies of DprE1 complexed with 15
sPBTZ. Recombinant M. tuberculosis DprE1 was overexpressed and purified as described 16 previously (5) to obtain highly concentrated and pure protein with bound flavin adenine 17 dinucleotide (FAD). Enzyme activities in the presence of MCZ, Ty38c and 11326127 were 18 measured as described previously to determine IC 50 (50% inhibitory concentrations) values for 19 both wild-type and C131S mutant DprE1 proteins (14) . solutions were pre-incubated at 37°C for 10 min before the intrinsic clearance assessment was 18 initiated by mixing the two solutions (50 µl of each; final compound concentration, 1 µg/ml) at 19 37°C. After 0, 5, 15, 30, and 60 min, the reactions were terminated by transferring 100 µl of the 20 reaction mixture into 100 µl of acetonitrile and placing the mixture on ice for 30 min for full 21 protein precipitation. Samples were then centrifuged at 12,000 x g for 10 min, and the (Dionex) to quantify the amount of parent compound remaining over time. Carbamazepine and 1 Nifedipine at the same concentrations were used as controls for low and high intrinsic clearances 2 respectively. 3
Anti-mycobacterial activity of 11626091 against chronic TB in mice. Female 4 BALB/cByJ mice, aged 5 to 6 weeks, were purchased from Charles River Laboratories (France). 5
Mice were infected with a low dose aerosol (100 -200 CFU/lung) of logarithmic-phase M. 6
tuberculosis H37Rv bacilli, then were allocated to experimental groups and returned to their 7 cages. Five mice were used per time point for each regimen. Treatment was initiated 4 weeks 8 after infection. 9
Macozinone (MCZ), 11626091, and isoniazid (INH) were prepared weekly in 0.5% 10 methylcellulose and administered at 25, 50, and 10 mg/kg, respectively, by gavage 5 days a week 11 for 4 weeks. In vivo efficacy of each treatment was assessed by CFU enumeration after plating 12 dilutions of the lung and spleen homogenates on 7H10 agar plates containing 10% OADC, 13 cycloheximide (10 μg/ml), and ampicillin (50 μg/ml). Plates were incubated for 4 weeks at 37°C 14 before CFU were enumerated. CFU counts were log10 transformed before analysis as mean 15 log10 CFU ± standard deviation (SD), and were compared by Student's t-test using GraphPad 16 Prism® version 7.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P values less than 17 0.05 were considered as statistically significant. 
